MAPT and Alzheimer disease: Activation of CYP46A1 through enzyme overexpression or positive allosteric modulation has demonstrated neuroprotective effects in various AD mouse models [77,273,274,275,276], and efavirenz treatment in iPSC-derived AD neurons has reduced cholesterol accumulation and attenuated both Aβ and tau pathology [277].